Severe Asthma Treatment Shows Promise for Sustained Remission

Adults with severe asthma may maintain clinical remission for two years or more with ongoing depemokimab treatment.

Updated on Oct. 21, 2026 in Asthma

A modern inhaler sits on a sterile white medical surface in a bright, professional clinic. — A study shows that nearly 60 percent of severe asthma patients treated with depemokimab sustained clinical remission through a second year. AI Illustration. Upload story photo >

Live Poll

Does achieving early clinical remission with asthma medication increase your trust in the therapy's long-term effectiveness?

Adults with severe asthma may maintain long-term clinical remission with the medication depemokimab. New data shows that 59% of patients who achieved remission after one year of treatment successfully sustained that status through a second year.

Why it matters

Achieving clinical remission with severe asthma can significantly reduce symptoms and breathing complications. This research highlights the potential for sustained health improvements, offering a clearer picture of treatment goals for patients managing the condition.

An integrated analysis of the 52-week SWIFT-1, SWIFT-2, and AGILE trials found that 59% of patients who reached clinical remission in year one maintained that status through year two. Remission was defined by the absence of exacerbations and oral corticosteroid use, plus specific lung function scores.

The players

FDA

The federal agency responsible for evaluating the safety and efficacy of medical treatments.

CHEST

The professional organization that hosts annual meetings for pulmonary and critical care medicine experts.

The details

Depemokimab works by targeting underlying inflammation to keep asthma symptoms at bay. Patients who achieved remission at year one saw an annualized exacerbation rate of 0.19, compared to 0.69 for those not in remission. Furthermore, those in the remission group experienced improved quality of life scores and a pre-bronchodilator lung capacity increase of 379 mL.

December 2025: Depemokimab received FDA approval for severe asthma.
October 20, 2026: Results were presented at the CHEST 2026 Annual Meeting.

Health Landscape

This analysis extends the findings of the primary SWIFT-1 and SWIFT-2 clinical trials by evaluating long-term outcomes through a two-year period. It reflects a shift in asthma care toward targeting clinical remission as a measurable benchmark for treatment success.

If you are living with severe asthma, these findings illustrate why reaching and maintaining remission is a key milestone for lung health. Talk to your doctor about your current treatment plan and whether your health goals include reaching these specific clinical metrics.

The takeaway

Patients managing severe asthma can look toward clinical remission as a viable target for improving quality of life and breathing capacity. Discuss your asthma control and current symptoms with your physician to see if your progress aligns with established clinical remission metrics.